Page last updated: 2024-11-03

prazosin and Parkinson Disease

prazosin has been researched along with Parkinson Disease in 8 studies

Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.

Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)

Research Excerpts

ExcerptRelevanceReference
"Mild dizziness/lightheadedness was more common in the TZ group, and three participants taking TZ dropped out because of dizziness and/or orthostatic hypotension."3.11A pilot to assess target engagement of terazosin in Parkinson's disease. ( Brinker, AN; Ernst, SE; Liu, L; Magnotta, VA; Narayanan, NS; Rauckhorst, AJ; Schultz, JL; Simmering, JE; Taylor, EB; Tayyari, F; Uc, EY; Welsh, MJ; Xu, J, 2022)
" Additional dose-response analyses were carried out."1.62Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease. ( Liu, L; Narayanan, NS; Pottegård, A; Simmering, JE; Welsh, MJ, 2021)
"We found slower disease progression, decreased PD-related complications, and a reduced frequency of PD diagnoses in individuals taking TZ and related drugs."1.51Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases. ( Cai, R; Chen, Z; Consiglio, A; Fernandez-Carasa, I; Gao, L; Han, Y; Ji, X; Li, Y; Liu, L; Narayanan, NS; Polgreen, PM; Raya, A; Schultz, JL; Simmering, JE; Su, W; Welsh, MJ; Yuan, Y; Zhang, Y; Zhao, C, 2019)
"Further, when the HAL (1 mg/kg) catalepsy score was maximal (at 120 min), the rats were subjected to cold stress (3 degrees C for 10 min) or treated with NA, AD (2 micrograms/kg, i."1.29Glucocorticoids attenuate haloperidol-induced catalepsy through adrenal catecholamines. ( Chopde, CT; Hote, MS; Mandhane, SN; Muthal, AV, 1995)

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19902 (25.00)18.7374
1990's1 (12.50)18.2507
2000's0 (0.00)29.6817
2010's2 (25.00)24.3611
2020's3 (37.50)2.80

Authors

AuthorsStudies
Schultz, JL2
Brinker, AN1
Xu, J1
Ernst, SE1
Tayyari, F1
Rauckhorst, AJ1
Liu, L3
Uc, EY1
Taylor, EB1
Simmering, JE3
Magnotta, VA1
Welsh, MJ3
Narayanan, NS3
Sardoiwala, MN1
Mohanbhai, SJ1
Karmakar, S1
Choudhury, SR1
Cai, R1
Zhang, Y1
Li, Y1
Fernandez-Carasa, I1
Consiglio, A1
Raya, A1
Polgreen, PM1
Yuan, Y1
Chen, Z1
Su, W1
Han, Y1
Zhao, C1
Gao, L1
Ji, X1
Foltynie, T1
Pottegård, A1
Cash, R2
Ruberg, M1
Raisman, R1
Agid, Y2
Chopde, CT1
Hote, MS1
Mandhane, SN1
Muthal, AV1
Lasbennes, F1
Sercombe, R1
Seylaz, J1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
a Randomized, Double Blind, Placebo Controlled Clinical Trial Exploring the Target Engagement and Tolerability of Terazosin Hydrochloride in Patients With Dementia With Lewy Bodies[NCT04760860]Phase 1/Phase 240 participants (Anticipated)Interventional2024-10-31Not yet recruiting
The Effect of alpha1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study[NCT05109364]Phase 215 participants (Anticipated)Interventional2022-09-23Recruiting
Assessing Target Engagement of Terazosin in Healthy Adults[NCT04551040]Phase 118 participants (Anticipated)Interventional2021-03-26Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for prazosin and Parkinson Disease

ArticleYear
Glycolysis as a therapeutic target for Parkinson's disease.
    The Lancet. Neurology, 2019, Volume: 18, Issue:12

    Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Drug Delivery Systems; Glycolysis; Humans; Parkins

2019

Trials

1 trial available for prazosin and Parkinson Disease

ArticleYear
A pilot to assess target engagement of terazosin in Parkinson's disease.
    Parkinsonism & related disorders, 2022, Volume: 94

    Topics: Adenosine Triphosphate; Dizziness; Humans; Parkinson Disease; Pilot Projects; Prazosin

2022

Other Studies

6 other studies available for prazosin and Parkinson Disease

ArticleYear
Hytrin loaded polydopamine-serotonin nanohybrid induces IDH2 mediated neuroprotective effect to alleviate Parkinson's disease.
    Biomaterials advances, 2022, Volume: 133

    Topics: alpha-Synuclein; Dopamine; Humans; Indoles; Neurodegenerative Diseases; Neuroprotective Agents; Park

2022
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease.
    JAMA neurology, 2021, 04-01, Volume: 78, Issue:4

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Cohort Studies; Databases,

2021
Adrenergic receptors in Parkinson's disease.
    Brain research, 1984, Nov-26, Volume: 322, Issue:2

    Topics: Clonidine; Dihydroalprenolol; Frontal Lobe; Humans; Locus Coeruleus; Neural Pathways; Norepinephrine

1984
Glucocorticoids attenuate haloperidol-induced catalepsy through adrenal catecholamines.
    Journal of neural transmission. General section, 1995, Volume: 102, Issue:1

    Topics: Adrenalectomy; Animals; Catalepsy; Catecholamines; Glucocorticoids; Haloperidol; Male; Parkinson Dis

1995
Adrenergic receptors on cerebral microvessels in control and parkinsonian subjects.
    Life sciences, 1985, Aug-12, Volume: 37, Issue:6

    Topics: Aged; Alprenolol; Capillaries; Cerebrovascular Circulation; Clonidine; Dihydroalprenolol; Humans; Ki

1985